UPDATE - Barclays Downgraded Edwards Lifesciences (EW) to Equalweight; Cautious Around Rollout and Cohort 'A' Noise
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $111.96 +3.21%
Rating Summary:
23 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 14 | New: 72
Rating Summary:
23 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 26 | Down: 14 | New: 72
Trade Now!
Join SI Premium – FREE
UPDATE - Barclays downgraded Edwards Lifesciences (NYSE: EW) from Overweight to Equalweight, price target lowered from $95 to $85.
Barclays analyst says, "...Past the rollout, we think there could be volatility around the Cohort A panel in 1H12, given the July 2011 FDA panel's cautious stance on adverse events/stroke and an aggressive rollout of Cohort B. Net-net, while we continue to be positive on the long-term potential of the TAVR market, we think that the market could be slower to develop and upcoming risks could cause the stock to retrace."
To see more ratings changes on EW, Click Here
Barclays analyst says, "...Past the rollout, we think there could be volatility around the Cohort A panel in 1H12, given the July 2011 FDA panel's cautious stance on adverse events/stroke and an aggressive rollout of Cohort B. Net-net, while we continue to be positive on the long-term potential of the TAVR market, we think that the market could be slower to develop and upcoming risks could cause the stock to retrace."
To see more ratings changes on EW, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Wells Fargo Upgrades Edwards Lifesciences (EW) to Overweight
- Wedbush Downgrades Chewy Inc. (CHWY) to Neutral
- Morgan Stanley Downgrades Synthomer Plc (SYNT:LN) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
